ABSTRACT
Background: Due to immunosuppressive oncologic therapy patients are at risk for infections. In case of COVID-19, patients have a high risk even to die due to this infection, especially when they have a progressive disease. But also dose-reductions, -modifications or postponing of chemotherapy cycles result in disease-progression and are associated with early deaths (1,2). In this study we offer patients at risk user-friendly technologies for transmitting biosignal-data and patient reported outcome monitoring (PROM) data for early detection of infections. Method(s): We designed a monocenter prospective cohort study using PROM via app and remote monitoring via photoplethysmography (PPG). The application of these technologies enables an early detection of infections and therefore initiation of medical interventions. The study is conducted as feasibility analysis;primary endpoints are adherence (according to wearing time) and technical robustness. Result(s): We expect study results in 4th quarter 2022. Discussion(s): The applied user friendly technologies can be used in the out-patient setting for transmission of biodata and symptoms;but also for a better communication between patients and physicians. This results in medical interventions at an early stage for treatment of infections. This study is conducted in a cooperation with the department of cardiology, using the infrastructure of the TUM telemedicine-center. Long-term objective ist to establish an expandable remote-monitoring infrastructure for the public health sector. Conclusion(s): By the use of remote-monitoring and PROM, we obtain an increase in safety for cancer patients undergoing immunosuppressive oncologic therapy during COVID-19 pandemia.